10 results on '"Barth RN"'
Search Results
2. Which cava anastomotic techniques are optimal regarding immediate and short-term outcomes after liver transplantation: A systematic review of the literature and expert panel recommendations.
- Author
-
Shaker TM, Eason JD, Davidson BR, Barth RN, Pirenne J, Imventarza O, Spiro M, Raptis DA, and Fung J
- Subjects
- Humans, Retrospective Studies, Portacaval Shunt, Surgical, Anastomosis, Surgical methods, Vena Cava, Inferior surgery, Liver Transplantation methods, Kava
- Abstract
Background: It has long been debated whether cava anastomosis should be performed with the piggyback technique or cava replacement, with or without veno-venous bypass (VVB), with or without temporary portocaval shunt (PCS) in the setting of liver transplantation., Objectives: To identify whether different cava anastomotic techniques and other maneuvers benefit the recipient regarding short-term outcomes and to provide international expert panel recommendations., Data Sources: Ovid MEDLINE, Embase, Scopus, Google Scholar, and Cochrane Central., Methods: A systematic review following PRISMA guidelines and recommendations using the GRADE approach derived from an international expert panel (CRD42021240979)., Results: Of 3205 records screened, 307 publications underwent full-text assessment for eligibility and 47 were included in qualitative synthesis. Four studies were randomized control trials. Eighteen studies were comparative. The remaining 25 were single-center retrospective noncomparative studies., Conclusion: Based on existing data and expert opinion, the panel cannot recommend one cava reconstruction technique over another, rather the surgical approach should be based on surgeon preference and center dependent, with special consideration toward patient circumstances (Quality of evidence: Low | Grade of Recommendation: Strong). The panel recommends against routine use of vevo-venous bypass (Quality of evidence: Very Low | Grade of Recommendation: Strong) and against the routine use of temporary porto-caval shunt (Quality of evidence: Very Low | Grade of Recommendation: Strong)., (© 2022 The Authors. Clinical Transplantation published by John Wiley & Sons Ltd.)
- Published
- 2022
- Full Text
- View/download PDF
3. COVID-19 in hospitalized liver transplant recipients: An early systematic review and meta-analysis.
- Author
-
Jayant K, Reccia I, Virdis F, Pyda JS, Bachul PJ, di Sabato D, Barth RN, Fung J, Baker T, and Witkowski P
- Subjects
- Aged, Aged, 80 and over, Carcinoma, Hepatocellular surgery, Female, Hospitalization, Humans, Liver Neoplasms surgery, Male, Middle Aged, COVID-19 epidemiology, Liver Transplantation, Transplant Recipients
- Abstract
Adverse clinical outcomes related to SARS-CoV-2 infection among liver transplant (LTx) recipients remain undefined. We performed a meta-analysis to determine the pooled prevalence of outcomes among hospitalized LTx recipients with COVID-19. A database search of literature published between December 1, 2019, and November 20, 2020, was performed per PRISMA guidelines. Twelve studies comprising 517 hospitalized LTx recipients with COVID-19 were analyzed. Common presenting symptoms were fever (71%), cough (62%), dyspnea (48%), and diarrhea (28%). Approximately 77% (95% CI, 61%-93%) of LTx recipients had a history of liver cirrhosis. The most prevalent comorbidities were hypertension (55%), diabetes (45%), and cardiac disease (21%). In-hospital mortality was 20% (95% CI, 13%-28%) and rose to 41% (95% CI, 19%-63%) (P < 0.00) with ICU admission. Additional subgroup analysis demonstrated a higher mortality risk in the elderly (>60-65 years) (OR 4.26; 95% CI, 2.14-8.49). There was no correlation in respect to sex or time since transplant. In summary, LTx recipients with COVID-19 had a high prevalence of dyspnea and gastrointestinal symptoms. In-hospital mortality was comparable to non-transplant populations with similar comorbidities but appeared to be less than what is reported elsewhere for cirrhotic patients (26%-40%). Importantly, the observed high case fatality in the elderly could be due to age-associated comorbidities., (© 2021 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.)
- Published
- 2021
- Full Text
- View/download PDF
4. Extracorporeal membrane oxygenation support following liver transplantation-A case series.
- Author
-
Goussous N, Akbar H, LaMattina JC, Hanish SI, Barth RN, and Bruno DA
- Subjects
- Adult, Female, Follow-Up Studies, Graft Rejection etiology, Graft Rejection mortality, Graft Survival, Heart Arrest etiology, Heart Arrest mortality, Humans, Male, Middle Aged, Postoperative Complications etiology, Postoperative Complications mortality, Respiratory Insufficiency etiology, Respiratory Insufficiency mortality, Retrospective Studies, Survival Rate, Treatment Outcome, Extracorporeal Membrane Oxygenation methods, Graft Rejection therapy, Heart Arrest therapy, Hospital Mortality trends, Liver Transplantation adverse effects, Postoperative Complications therapy, Respiratory Insufficiency therapy
- Abstract
Background: Postoperative severe cardiopulmonary failure carries a high rate of mortality. Extracorporeal membrane oxygenation (ECMO) can be used as a salvage therapy when conventional therapies fail., Methods: We retrospectively reviewed our experience with ECMO support in the early postoperative period after liver transplant between September 2011 and May 2016., Results: Out of 537 liver transplants performed at our institution, seven patients required ECMO support with a median age of 52 and a median MELD score of 28. Veno-venous ECMO was used in four patients with severe respiratory failure while the rest required veno-arterial ECMO for circulatory failure. The median time from transplant to cannulation was 3 days with a median duration of ECMO support of 7 days. All patients except one were successfully decannulated. The median hospital length of stay was 58 days with an in-hospital mortality of 28.6%., Conclusion: Extracorporeal membrane oxygenation can be considered a viable rescue therapy in the setting of severe postoperative cardiopulmonary failure. Extracorporeal membrane oxygenation therapy was successful in saving patients who were otherwise unsalvageable., (© 2019 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.)
- Published
- 2019
- Full Text
- View/download PDF
5. Alemtuzumab induction and belatacept maintenance in marginal pathology renal allografts.
- Author
-
Sparkes T, Ravichandran B, Opara O, Ugarte R, Drachenberg CB, Philosophe B, Bromberg JS, and Barth RN
- Subjects
- Antineoplastic Agents, Immunological pharmacology, Female, Follow-Up Studies, Glomerular Filtration Rate, Graft Rejection etiology, Graft Rejection pathology, Humans, Immunosuppressive Agents therapeutic use, Kidney Failure, Chronic surgery, Kidney Function Tests, Male, Middle Aged, Pilot Projects, Postoperative Complications drug therapy, Postoperative Complications etiology, Postoperative Complications pathology, Prognosis, Prospective Studies, Risk Factors, Transplantation, Homologous, Abatacept pharmacology, Alemtuzumab pharmacology, Graft Rejection drug therapy, Graft Survival drug effects, Induction Chemotherapy methods, Kidney Transplantation adverse effects, Maintenance Chemotherapy methods
- Abstract
We performed a prospective, 12-month, single-center, nonrandomized, open-label pilot study to investigate the use of belatacept therapy combined with alemtuzumab induction in renal allografts with preexisting pathology, as these kidneys may be more susceptible to additional toxicity when exposed to calcineurin inhibitors posttransplant. Nineteen belatacept recipients were matched retrospectively to a cohort of tacrolimus recipients on the basis of preimplantation pathology. The estimated glomerular filtration rate was not significantly different between belatacept and tacrolimus recipients at either 3 or 12 months posttransplant (59 vs 45, P = 0.1 and 56 vs 48 mL/min/1.72/m
2 , P = 0.3). Biopsy-proven acute rejection rates at 12 months were 26% in belatacept recipients and 16% in tacrolimus recipients (P = 0.7). Graft survival at 1 year was 89% in both groups. Alemtuzumab induction combined with either calcineurin inhibitor or costimulatory blockade therapies resulted in similar acceptable one-year outcomes in kidneys with preexisting pathologic changes. Longer-term follow-up may be necessary to identify preferential strategies to improve outcomes of kidneys at a higher risk for poor function (ClinicalTrials.gov-NCT01496417)., (© 2019 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.)- Published
- 2019
- Full Text
- View/download PDF
6. Diabetic nephropathy after kidney transplantation in patients with pretransplantation type II diabetes: A retrospective case series study from a high-volume center in the United States.
- Author
-
Cimeno A, Munley J, Drachenberg C, Weir M, Haririan A, Bromberg J, Barth RN, and Scalea JR
- Subjects
- Diabetic Nephropathies pathology, Female, Follow-Up Studies, Graft Rejection pathology, Graft Survival, Humans, Male, Middle Aged, Prognosis, Retrospective Studies, Risk Factors, United States, Diabetes Mellitus, Type 2 surgery, Diabetic Nephropathies etiology, Graft Rejection etiology, Hospitals, High-Volume statistics & numerical data, Kidney Transplantation adverse effects, Postoperative Complications
- Abstract
Background: Patients with type II diabetes mellitus (DM) undergoing renal transplantation are at risk of diabetic nephropathy (DN) in the transplanted kidney. The true risk of developing post-transplantation DN is unknown, and post-transplantation DN is poorly characterized in the literature., Methods: The biopsy database at the University of Maryland Medical Center was queried for kidney transplant biopsies which demonstrated evidence of DN. The time from transplantation to biopsy-proven DN (time to diagnosis, TTD) was calculated and analyzed in the context of demographics, serum creatinine, and onset of diabetes. By extrapolating the total number of patients who developed DN in the last 2 years, we estimated the recurrence rate of DN., Results: Sixty patients whose renal biopsies met criteria were identified. The mean age was 56.6 (±1.58) years, and the mean creatinine level at time of biopsy was 1.65 (±0.12) mg/dL. Simultaneous pathological diagnoses were frequent on kidney biopsy; rejection was present at variable rates: classes I, IIA, IIB, and III were 5.0%, 66.7%, 18.4%, and 10%, respectively. The mean TTD was 1456 (±206) days. TTD was significantly shorter for patients receiving a cadaveric vs living donor renal transplant (1118 ± 184 vs 2470 ± 547 days, P = 0.004). Older patients (r = 0.378, P = 0.003) and patients with higher serum creatinine (r = 0.282, P = 0.029) had shorter TTDs. Extrapolations showed that 74.7% of patients would be free of DN 10 years after renal transplantation., Conclusions: Diabetic nephropathy occurs after transplantation, and this appears to be due to both donor and recipient-derived factors. Encouragingly, our estimates suggest that as many as 75% of patients may be free of DN at 10 years following kidney transplantation., (© 2018 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.)
- Published
- 2018
- Full Text
- View/download PDF
7. Resolution of donor non-alcoholic fatty liver disease following liver transplantation.
- Author
-
Posner AD, Sultan ST, Zaghloul NA, Twaddell WS, Bruno DA, Hanish SI, Hutson WR, Hebert L, Barth RN, and LaMattina JC
- Subjects
- Adult, Aged, Biopsy, Female, Humans, Liver pathology, Liver surgery, Male, Middle Aged, Non-alcoholic Fatty Liver Disease diagnosis, Non-alcoholic Fatty Liver Disease pathology, Outcome Assessment, Health Care, Retrospective Studies, Transplantation, Homologous, Donor Selection, Hepatectomy, Liver Transplantation, Living Donors, Non-alcoholic Fatty Liver Disease surgery
- Abstract
Introduction: Transplant surgeons conventionally select against livers displaying high degrees (>30%) of macrosteatosis (MaS), out of concern for primary non-function or severe graft dysfunction. As such, there is relatively limited experience with such livers, and the natural history remains incompletely characterized. We present our experience of transplanted livers with high degrees of MaS and microsteatosis (MiS), with a focus on the histopathologic and clinical outcomes., Methods: Twenty-nine cases were identified with liver biopsies available from both the donor and the corresponding liver transplant recipient. Donor liver biopsies displayed either MaS or MiS ≥15%, while all recipients received postoperative liver biopsies for cause., Results: The mean donor MaS and MiS were 15.6% (range 0%-60%) and 41.3% (7.5%-97.5%), respectively. MaS decreased significantly from donor (M=15.6%) to recipient postoperative biopsies (M=0.86%), P<.001. Similarly, MiS decreased significantly from donor biopsies (M=41.3%) to recipient postoperative biopsies (M=1.8%), P<.001. At a median of 68 days postoperatively (range 4-384), full resolution of MaS and MiS was observed in 27 of 29 recipients., Conclusions: High degrees of MaS and MiS in donor livers resolve in recipients following liver transplantation. Further insight into the mechanisms responsible for treating fatty liver diseases could translate into therapeutic targets., (© 2017 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.)
- Published
- 2017
- Full Text
- View/download PDF
8. Sequential kidney-liver transplantation from the same living donor for lecithin cholesterol acyl transferase deficiency.
- Author
-
Ahmad SB, Miller M, Hanish S, Bartlett ST, Hutson W, Barth RN, and LaMattina JC
- Subjects
- Adult, Female, Humans, Kidney Failure, Chronic etiology, Lecithin Cholesterol Acyltransferase Deficiency complications, Male, Kidney Failure, Chronic surgery, Kidney Transplantation methods, Lecithin Cholesterol Acyltransferase Deficiency surgery, Liver Transplantation methods, Living Donors
- Abstract
Background: Lecithin cholesterol acyl transferase (LCAT) deficiency is a rare autosomal recessive disorder of lipoprotein metabolism that results in end-stage renal disease (ESRD) necessitating transplantation. As LCAT is produced in the liver, combined kidney and liver transplantation was proposed to cure the clinical syndrome of LCAT deficiency., Methods: A 29-year-old male with ESRD secondary to LCAT deficiency underwent a sequential kidney-liver transplantation from the same living donor (LD). One year following the kidney transplant, auxiliary partial orthotopic liver transplant (APOLT) of a left lateral segment from the same donor was performed., Results: At 5 years follow-up, there have been no major complications, readmissions, or rejection episodes. Serum lipid abnormalities recurred within the first year, but liver and kidney allograft function remains intact., Conclusion: Few cases of sequential transplantation from the same LD have been performed in adults. This is the first APOLT and multi-organ transplant performed for LCAT deficiency. Sequential organ transplant from the same LD for ESRD secondary to a metabolic disorder of the liver is feasible in adults and should be further investigated., (© 2016 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.)
- Published
- 2016
- Full Text
- View/download PDF
9. Validation of the Maryland Aggregate Pathology Index (MAPI), a pre-implantation scoring system that predicts graft outcome.
- Author
-
Philosophe B, Malat GE, Soundararajan S, Barth RN, Manitpisikul W, Wilson NS, Ranganna K, Drachenberg CB, Papadimitriou JC, Neuman BP, and Munivenkatappa RB
- Subjects
- Female, Follow-Up Studies, Glomerular Filtration Rate, Graft Rejection mortality, Humans, Kidney Function Tests, Male, Maryland, Middle Aged, Patient Selection, Preimplantation Diagnosis statistics & numerical data, Prognosis, Risk Factors, Graft Rejection diagnosis, Graft Survival, Kidney Failure, Chronic surgery, Kidney Transplantation methods, Preimplantation Diagnosis methods
- Abstract
Predicting graft outcome after renal transplantation based on donor histological features has remained elusive and is subject to institutional variability. We have shown in a retrospective study that the Maryland Aggregate Pathology Index score reliably predicts graft outcome. We sought to validate the scoring system in our center and a second transplant center. We analyzed 140 deceased donor kidneys pre-implantation biopsies from center 1 and 65 from center 2. The patients had a mean follow-up of 695 ± 424 and 656 ± 305 d respectively. Although MAPI scores were similar, there were significant differences in donor and recipient parameters between both centers. Despite this, MAPI was predictive of graft outcome for both centers by Cox univariate, multivariate and time dependent ROC analysis. For center 1 and 2, three yr graft survival within each MAPI group was statistically equivalent. The three-yr graft survival at center 1 for low, intermediate, and high MAPI groups were 84.3%, 56.5%, and 50.0%, respectively, p ≤ 0.0001, and at center 2 were 83.3%, 33.3%, and 33.3%, p = 0.006. MAPI, which is based on a pre-implantation biopsy, demonstrated similar predictive and outcome results from both centers. As expanded criteria donors (ECD) criteria have redefined marginal kidneys, MAPI has the potential to further define ECD kidneys, increase utilization, and ultimately improve outcomes., (© 2014 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.)
- Published
- 2014
- Full Text
- View/download PDF
10. Antibody-mediated rejection of renal allograft in combined liver-kidney transplant.
- Author
-
Barth RN, Campos L, Kukuruga DL, Drachenberg C, and Philosophe B
- Subjects
- ABO Blood-Group System immunology, Complement C4b metabolism, Graft Rejection pathology, Histocompatibility Testing, Humans, Kidney Transplantation adverse effects, Liver Transplantation adverse effects, Male, Middle Aged, Peptide Fragments metabolism, Transplantation, Homologous, Graft Rejection immunology, HLA Antigens immunology, Isoantibodies immunology, Kidney Transplantation immunology, Liver Transplantation immunology, Postoperative Complications, Renal Dialysis
- Abstract
Liver transplantation is performed based on ABO blood type compatibility without dependence on crossmatch results. Combined liver-kidney transplantation (CLKT) is similarly performed without dependence of crossmatch results as the liver is thought to confer protection to the renal allograft against alloantibody. We report a case of CLKT in a sensitized patient with antibody-mediated rejection (AMR) of the renal allograft. AMR was confirmed with C4d staining and serial monitoring of donor-specific antibody (DSA). Despite intensive therapy directed against AMR and the presence of the liver allograft, the patient demonstrated increasing titers of alloantibody, never demonstrated adequate renal function, and ultimately expired after two months. This result demonstrates the potential for AMR of the renal allograft in sensitized recipients of CLKT., (© 2009 John Wiley & Sons A/S.)
- Published
- 2010
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.